Cargando…

Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia

The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB) by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic instability, shifting the normal process of the cell cycle, leading the cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz-y-Miño, César, López-Cortés, Andrés, Muñoz, María José, Castro, Bernardo, Cabrera, Alejandro, Sánchez, María Eugenia
Formato: Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Genética 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036142/
https://www.ncbi.nlm.nih.gov/pubmed/21637572
http://dx.doi.org/10.1590/S1415-47572010005000095
_version_ 1782197858904047616
author Paz-y-Miño, César
López-Cortés, Andrés
Muñoz, María José
Castro, Bernardo
Cabrera, Alejandro
Sánchez, María Eugenia
author_facet Paz-y-Miño, César
López-Cortés, Andrés
Muñoz, María José
Castro, Bernardo
Cabrera, Alejandro
Sánchez, María Eugenia
author_sort Paz-y-Miño, César
collection PubMed
description The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB) by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic instability, shifting the normal process of the cell cycle, leading the cells to develop into cancer. In this work we analyzed exon 18 of the hRAD54 gene, which has been previously reported by our group to carry a silent polymorphism, 2290 C/T (Ala730Ala), associated to meningiomas. We performed a PCR-SSCP method to detect the polymorphism in 239 samples including leukemia and normal control population. The results revealed that the 2290 C/T polymorphism has frequencies of 0.1 for the leukemia and 0.1 for the control group. These frequencies show no statistical differences. Additionally, we dissected the leukemia group in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) to evaluate the polymorphism. The frequencies found in these subgroups were 0.14 for CML and 0.05 for ALL. We found statistically significant differences between CML patients and the control group (p < 0.05) but we did not find significant differences between ALL and the control group (p > 0.05). These results suggest a possible link between the 2290 C/T polymorphism of the hRAD54 gene and CML.
format Text
id pubmed-3036142
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Sociedade Brasileira de Genética
record_format MEDLINE/PubMed
spelling pubmed-30361422011-06-02 Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia Paz-y-Miño, César López-Cortés, Andrés Muñoz, María José Castro, Bernardo Cabrera, Alejandro Sánchez, María Eugenia Genet Mol Biol Human and Medical Genetics The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB) by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic instability, shifting the normal process of the cell cycle, leading the cells to develop into cancer. In this work we analyzed exon 18 of the hRAD54 gene, which has been previously reported by our group to carry a silent polymorphism, 2290 C/T (Ala730Ala), associated to meningiomas. We performed a PCR-SSCP method to detect the polymorphism in 239 samples including leukemia and normal control population. The results revealed that the 2290 C/T polymorphism has frequencies of 0.1 for the leukemia and 0.1 for the control group. These frequencies show no statistical differences. Additionally, we dissected the leukemia group in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) to evaluate the polymorphism. The frequencies found in these subgroups were 0.14 for CML and 0.05 for ALL. We found statistically significant differences between CML patients and the control group (p < 0.05) but we did not find significant differences between ALL and the control group (p > 0.05). These results suggest a possible link between the 2290 C/T polymorphism of the hRAD54 gene and CML. Sociedade Brasileira de Genética 2010 2010-12-01 /pmc/articles/PMC3036142/ /pubmed/21637572 http://dx.doi.org/10.1590/S1415-47572010005000095 Text en Copyright © 2010, Sociedade Brasileira de Genética. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Human and Medical Genetics
Paz-y-Miño, César
López-Cortés, Andrés
Muñoz, María José
Castro, Bernardo
Cabrera, Alejandro
Sánchez, María Eugenia
Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
title Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
title_full Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
title_fullStr Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
title_full_unstemmed Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
title_short Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
title_sort relationship of an hrad54 gene polymorphism (2290 c/t) in an ecuadorian population with chronic myelogenous leukemia
topic Human and Medical Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036142/
https://www.ncbi.nlm.nih.gov/pubmed/21637572
http://dx.doi.org/10.1590/S1415-47572010005000095
work_keys_str_mv AT pazyminocesar relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia
AT lopezcortesandres relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia
AT munozmariajose relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia
AT castrobernardo relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia
AT cabreraalejandro relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia
AT sanchezmariaeugenia relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia